AB045. P016. Profile of neoepitopes on human pancreas tumor tissue by proteomics
Abstract

AB045. P016. Profile of neoepitopes on human pancreas tumor tissue by proteomics

Kenji Fujiwara, Pingbo Zhang, Lei Zheng

Johns Hopkins School of Medicine, Baltimore, MD, USA


Abstract: Mutated peptide ligands could be attractive targets for cancer immunotherapy. For direct identification of clinically relevant neoepitopes, we have surveyed the pancreatic cancer-associated immunopeptidome by using advanced mass spectrometry (MS) analysis. Peptides are biochemically purified from human leucocyte antigens (HLA) class I and II binding peptides from pancreas tumors followed by sample clean using C18 columns. The purified peptides were analyzed by Q Exactive plus hybrid quadrupole-Orbitrap mass spectrometer, followed by bioinformatics analysis. Totally, we identified novel 34,247 peptide sequences from HLA class I binding peptides. The distribution of peptide length showed that 9-amino acid (AA) are the most abundant, followed by 10-AA and 8-AA, with a frequency of 3,580, 2,463, and 2,368 respectively. We will do genomic sequencing to verify the proteomic profile of these neoepitopes.


doi: 10.21037/apc.2018.AB045


Cite this article as: Fujiwara K, Zhang P, Zheng L. Profile of neoepitopes on human pancreas tumor tissue by proteomics. Ann Pancreat Cancer 2018;1:AB045. doi: 10.21037/apc.2018.AB045

Download Citation